

**Ambulatory measures owned and maintained by the NCQA**Technical specifications: [http://www.ncqa.org/communications/news/nqf\\_endorsement.htm](http://www.ncqa.org/communications/news/nqf_endorsement.htm)NDC codes: 2005 Final list <http://www.ncqa.org/Programs/HEDIS/hedis2005NDCFinal.htm>**Endorsed**

ASTHMA/RESPIRATORY ILLNESS			
TOPIC	MEASURE	IP OWNER	USE
Appropriate Treatment for Children with Upper Respiratory Infection	Percentage of patients who were given a diagnosis of upper respiratory infection (URI) and were not dispensed an antibiotic prescription on or 3 days after the episode date	NCQA#	A
Appropriate Testing for Children with Pharyngitis	Percentage of patients who were diagnosed with pharyngitis, prescribed an antibiotic and who received a group A streptococcus test for the episode	NCQA#	A
BEHAVIORAL HEALTH/DEPRESSION			
TOPIC	MEASURE	IP OWNER	USE
Optimal Practitioner Contacts for Medication Management	Percentage of patients who were diagnosed with a new episode of depression and treated with antidepressant medication and had at least three follow-up contacts with a primary care practitioner or mental health practitioner coded with a mental health diagnosis during the 84-day (12 week) Acute Treatment Phase	NCQA#	A
Effective Acute Phase Treatment	Percentage of patients who were diagnosed with a new episode of depression and treated with antidepressant medication and remained on an antidepressant drug during the entire 84-day (12-week) Acute Treatment Phase	NCQA#	A
Effective Continuation Phase Treatment	Percentage of patients who were diagnosed with a new episode of depression and treated with antidepressant	NCQA#	A

	medication and remained on an antidepressant for at least 180 days (6 months)		
<b>DIABETES</b>			
<b>TOPIC</b>	<b>MEASURE</b>	<b>IP OWNER</b>	<b>USE</b>
A1c Management (Screen)	Percentage of patients with one or more A1c test(s)	NCQA#	A
A1c Management (Control)	Percentage of patients with most recent A1c level > 9.0% (poor control)	NCQA#	A
Blood Pressure Management	Percentage of patients with most recent BP < 140/90 mm Hg	NCQA#	A
Lipid Management	Percentage of patients with at least one Low Density Lipoprotein cholesterol (LDL-C) test	NCQA#	A
LDL Cholesterol Level (<130mg/dL)	Percentage of patients with most recent LDL-C < 130	NCQA#	A
LDL Cholesterol Level (<100mg/dL)	Percentage of patients with most recent LDL-C < 100mg/dL	NCQA#	A
Urine Protein Screening	Percentage of patients with at least one test for microalbumin during the measurement year; or who had evidence of medical attention for existing nephropathy (diagnosis of nephropathy or documentation of microalbuminuria or albuminuria)	NCQA#	A
Eye Examination	Percentage of patients who received a dilated eye exam or seven standard field stereoscopic photos with interpretation by an ophthalmologist or optometrist or imaging validated to match diagnosis from these photos during the reporting year, or during the prior year, if patient is at low risk* for retinopathy  *Patient is considered low risk if the following criterion is met: has no evidence of retinopathy in the prior year.	NCQA#	A
Foot Examination	Percentage of eligible patients receiving at least one foot exam, defined in any manner	NCQA#	A
Smoking Cessation	Percentage of patients whose smoking status was ascertained and documented annually	NCQA#	A

HEART DISEASE			
TOPIC	MEASURE	IP OWNER	USE
CAD: Lipid Screen	Percentage of patients discharged from the hospital after AMI, CABG, and PTCA within the measurement year receiving at least one LDL-C screening	NCQA#	A
CAD: LDL Cholesterol Level	Percentage of patients discharged from the hospital after AMI, CABG, and PTCA within the measurement year with LDL-C test results < 130mg/dL and < 100mg/dL	NCQA#	A
HYPERENSION			
TOPIC	MEASURE	IP OWNER	USE
Blood Pressure Control	Percentage of patients with last BP < 140/90 mm Hg	CMS/ NCQA#	QI
PREVENTION, IMMUNIZATION AND SCREENING			
TOPIC	MEASURE	IP OWNER	USE
€Advising Smokers to Quit	Percentage of patients who received advise to quit smoking	NCQA#	A
€Discussing Smoking Cessation Medication	Percentage of patients whose practitioner recommended or discussed smoking cessation medications	NCQA#	A
€Discussing Smoking Strategies	Percentage of patients whose practitioner recommended or discussed smoking cessation methods or strategies	NCQA#	A
¥Discussing Urinary Incontinence	Percentage patients who reported having a problem with urine leakage in the last six months and who discussed their urine leakage problem with their current practitioner	NCQA#	A
¥Receiving Urinary Incontinence Treatment	Percentage of patients who reported having a problem with urine leakage in the last six months and discussed it with their current practitioner and who received	NCQA#	A

	treatment for their current urine leakage problem		
*Flu Shots for Older Adults	Percentage of patients 65 and over who received an influenza vaccination	CMS/ NCQA#	A
*Flu Shots for Older Adults Aged 50-64	Percentage of patients age 50-64 who received an influenza vaccination	CMS/ NCQA#	A
Pneumonia Vaccination	Percentage of patients who ever received a pneumococcal vaccination	CMS/ NCQA#	A

**Pending**

Subject to revote by NQF in the near future. Please check back for status.

ASTHMA/RESPIRATORY ILLNESS			
TOPIC	MEASURE	IP OWNER	USE
Asthma: Use of Appropriate Medications for People with Asthma	Percentage of patients who were identified as having persistent asthma during the year prior to the measurement year and who were dispensed a prescription for either an inhaled corticosteroid or acceptable alternative medication during the measurement year	NCQA#	A
BONE CONDITIONS			
TOPIC	MEASURE	IP OWNER	USE
Osteoporosis Management in Women Who had a Fracture	Percentage of women who suffered a fracture, and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis in the 6 months after date of fracture	NCQA#	A
PREVENTION, IMMUNIZATION AND SCREENING			
TOPIC	MEASURE	IP OWNER	USE
Childhood Immunization Status	Percentage of patients who turned 2 years old during the measurement year who had	NCQA#	A

	four DTaP/DT, three IPV, one MMR, three H influenza type B, three hepatitis B and one chicken pox vaccine (VZV) by the time period specified and by the child's second birthday		
Breast Cancer Screening	Percentage of women who had a mammogram during the measurement year or year prior to the measurement year	CMS/ NCQA#	QI
Colorectal Cancer Screening	Percentage of patients who had appropriate screening for colorectal cancer	NCQA#	A
Cervical Cancer Screening	Percentage of women who received one or more Pap tests during the measurement year or the two years prior to the measurement year.	NCQA#	QI
<b>HEART DISEASE</b>			
<b>TOPIC</b>	<b>MEASURE</b>	<b>IP OWNER</b>	<b>USE</b>
CAD: Beta-Blocker Therapy-after a heart attack	Percentage of patients hospitalized with an AMI during the measurement year who were prescribed beta-blocker therapy	NCQA#	A

**A** = Recommended by developer for public reporting/accountability

**QI**= Recommended by developer for internal quality improvement

**€**= Measure Triad

**¥** = Measure Pair

**#** =This performance measure was developed by and is owned by at he National Committee for Quality Assurance ("NCQA"). This performance measure is not a clinical guideline and does not establish a standard of medical care. NCQA makes no representations, warranties or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures.

**NCQA Notice of Use:** Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not a commercial use. Commercial use of a measure does require the prior written consent of the measure developer and commercial uses may be subject to a license agreement at the discretion of the measure developer. As used herein, a "commercial use" refers to any sale, license, or

distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain, (even if there is no actual charge for inclusion of the measure).